Castle Biosciences News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

05.10.23	DecisionDx®-Melanoma Outperforms Memorial Sloan Kettering Cancer Center (MSKCC) Nomogram in Predicting Sentinel Lymph Node Positivity in Patients with Cutaneous Melanoma (Businesswire)
02.10.23	Castle Biosciences Shares New Data Demonstrating Ability of TissueCypher® Test Results to Inform Clinical Decision-Making in Patients with Non-Dysplastic Barrett’s Esophagus (Businesswire)
25.09.23	Castle Biosciences, Leading Skin Cancer Expert, Darrell Rigel, M.D., M.S., and IMPACT Melanoma Board Member to Ring Nasdaq Closing Bell on Sept. 27, 2023, to Raise Awareness of Melanoma (Businesswire)
19.09.23	Castle Biosciences Ranked Third Among 2023 Top Workplaces in the Healthcare Industry (Businesswire)
14.09.23	TissueCypher® Barrett’s Esophagus Test Outperformed Standard of Care in Risk-Stratifying Patients with Barrett’s Esophagus (Businesswire)
12.09.23	Castle Biosciences Announces Receipt of New York Laboratory Permit for Pittsburgh Laboratory (Businesswire)
08.09.23	TissueCypher® Provides Clinically-Impactful Risk Stratification in Patients with Barrett’s Esophagus (Businesswire)
06.09.23	Castle Biosciences to Highlight Clinical Value of IDgenetix® Test at Psych Congress 2023 (Businesswire)
05.09.23	Castle Biosciences to Participate in Upcoming Investor Conferences (Businesswire)
07.08.23	New Publication Highlights the Ability of the TissueCypher® Barrett’s Esophagus Test to Improve and Standardize the Clinical Management of Low-Grade Dysplasia in Patients with Barrett’s Esophagus (Businesswire)
01.08.23	Castle Biosciences to Present at the Canaccord Genuity 43rd Annual Growth Conference (Businesswire)
19.07.23	Castle Biosciences to Release Second Quarter 2023 Financial Results and Host Conference Call on Wednesday, Aug. 2 (Businesswire)
18.07.23	Castle Biosciences to Host Second Annual Castle Cares Charity Walk (Businesswire)
17.07.23	Castle Biosciences Honored as an Arizona Top Workplace for the Second Consecutive Year (Businesswire)
07.07.23	Castle Biosciences to Present New DecisionDx®-SCC and DecisionDx®-Melanoma Data at the American Head & Neck Society’s (AHNS) 11th International Conference on Head and Neck Cancer (Businesswire)
30.06.23	Study Data from Castle Biosciences’ Collaboration with the National Cancer Institute’s SEER Program Registries Published in JCO Precision Oncology (Businesswire)
20.06.23	Castle Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (Businesswire)
03.06.23	Castle Biosciences to Share New Data on DecisionDx®-Melanoma and DecisionDx®-UM at the 2023 ASCO Annual Meeting (Businesswire)
31.05.23	IDgenetix® Shown to Significantly Improve Medication Response and Remission Rates in Patients with Major Depressive Disorder (Businesswire)
30.05.23	Castle Biosciences Celebrates Skin Cancer Awareness Month (Businesswire)
26.05.23	Castle Biosciences’ Abstracts at Digestive Disease Week (DDW) Annual Meeting Selected as "Posters of Distinction” by the American Gastroenterological Association (AGA) Institute Council (Businesswire)
22.05.23	Castle Biosciences Opens New State-of-the-Art Laboratory in Pittsburgh (Businesswire)
15.05.23	Castle Biosciences’ TissueCypher® Barrett's Esophagus Test Receives 2023 MedTech Breakthrough Award for Artificial Intelligence Innovation (Businesswire)
28.04.23	Castle Biosciences Collaborates with IMPACT Melanoma to Provide Free Sunscreen to Cyclists Participating in the Bike MS: Texas MS 150 2023 Cycling Event (Businesswire)
25.04.23	DecisionDx®-Melanoma Provides Improved Risk Stratification Over American Joint Committee on Cancer (AJCC) Staging Alone in Stage I Melanoma Patients (Businesswire)
20.04.23	TissueCypher® Test Results Can Increase the Likelihood of Appropriate Management Decisions for Barrett’s Esophagus Patients with Low-Grade Dysplasia (Businesswire)
19.04.23	Castle Biosciences to Release First Quarter 2023 Financial Results and Host Conference Call on Wednesday, May 3 (Businesswire)
12.04.23	Castle Biosciences to Present at the 22nd Annual Needham Virtual Healthcare Conference (Businesswire)
14.03.23	Castle Biosciences to Present at the KeyBanc Capital Markets Virtual Life Sciences & MedTech Investor Forum (Businesswire)
10.03.23	Castle Biosciences to Highlight Clinical Value of Its Skin Cancer Tests at the 2023 American Academy of Dermatology (AAD) Annual Meeting (Businesswire)
24.02.23	Castle Biosciences’ Chief Financial Officer Frank Stokes Selected Among the Top 25 CFOs of Houston for 2023 by Finance & Investing (Businesswire)
22.02.23	Data Presentation at 2023 Winter Clinical - Miami™ Highlights Use of DecisionDx®-Melanoma to Guide SLNB Surgery Decisions in Head and Neck Tumors (Businesswire)
07.02.23	Castle Biosciences to Release Fourth Quarter and Full-Year 2022 Financial Results and Host Conference Call on Tuesday, Feb. 28, 2023 (Businesswire)
01.02.23	Castle Biosciences Earns a Top Workplaces USA Award for the Second Consecutive Year (Businesswire)
23.01.23	Castle Biosciences’ Medical Director to Present at the Precision Medicine World Conference 2023 (Businesswire)
17.01.23	Data Presentations at 2023 Winter Clinical Dermatology Conference - Hawaii® Support Clinical Value of Castle Biosciences’ Skin Cancer Test Portfolio (Businesswire)
09.01.23	Castle Biosciences Announces Preliminary Fourth Quarter and Full-Year 2022 Results (Businesswire)
09.01.23	Castle Biosciences Expects 2022 Revenue To Meet Or Exceed Top End Of Guided Range (RTTNews)
21.11.22	Castle Biosciences Receives Accreditation from the College of American Pathologists for its Pittsburgh Clinical Laboratory (Businesswire)
17.11.22	Research Published in Melanoma Management Finds that 99% of Patients with Uveal Melanoma Tested with DecisionDx®-UM Gain Value from the Results (Businesswire)
15.11.22	Castle Biosciences Presents New Data Demonstrating the Clinical Utility and Value of DecisionDx®-SCC in Moderately and Poorly Differentiated Cutaneous Squamous Cell Carcinoma Tumors (Businesswire)
14.11.22	Castle Biosciences Named a Houston Chronicle Top Workplace for the Second Consecutive Year (Businesswire)
01.11.22	Castle Biosciences to Present at Upcoming Investor Conferences (Businesswire)
27.10.22	Castle Biosciences Presents New Data from Collaboration with the National Cancer Institute’s (NCI) Surveillance, Epidemiology and End Results (SEER) Program (Businesswire)
20.10.22	New Data from DECIDE Study Show the Significant Role of DecisionDx®-Melanoma Test Results and Patient Preference in Decisions to Perform the Sentinel Lymph Node Biopsy (SLNB) Surgical Procedure (Businesswire)
19.10.22	Castle Biosciences to Release Third Quarter 2022 Financial Results and Host Conference Call on Wednesday, Nov. 2 (Businesswire)
11.10.22	Castle Biosciences Presents Case Study Showcasing the Diagnostic Performance of DiffDx®-Melanoma at the College of American Pathologists 2022 (CAP22) Annual Meeting (Businesswire)
21.09.22	Castle Biosciences Presents Clinical Use Scenarios for Its Diagnostic Gene Expression Profile Tests at Maui Derm NP+PA Fall 2022 Conference (Businesswire)
20.09.22	Castle Biosciences Presents Foundational Guideposts and Three-Year Financial Targets at 2022 Investor Day (Businesswire)
13.09.22	Castle Biosciences Honored with a 2022 AZBio Fast Lane Award from the Arizona Bioindustry Association (Businesswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Zurich Insur Gr	547.60	3.13 %	K V
Logitech Intl	70.26	2.57 %	K V
Givaudan	3’919.00	1.45 %	K V
ABB	49.58	1.08 %	K V
Swiss Re	127.20	0.99 %	K V
Holcim	89.86	-0.24 %	K V
Sika	229.00	-0.35 %	K V
Swisscom	505.50	-0.49 %	K V
Nestle	75.96	-0.73 %	K V
CieFinRichemont	117.65	-0.80 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Castle Biosciences Inc Registered Shs

Aktien Top/Flop

Meistgelesene Nachrichten